

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 08-129885- -00002-0000

Fecha: 2009-03-19 16:38:44 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 70

AS: 108.822

Señora Jefe

DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. S. D.

RESPUESTA A OFICIO 0611 DEL 23 DE ENERO DE 2009

REF: Expediente No. 08 129.885 - Solicitud de Patente Entrada en Fase Nacional
Corresp. a la Solicitud Internacional PCT/US2007/070513

a favor de **GENENTECH, INC.**

Titulada: ANTICUERPOS ANTI-DLL4 Y MÉTODOS QUE LOS USAN.

JUAN PABLO CADENA SARMIENTO, vecino de Bogotá, portador de la tarjeta profesional No. 57492, obrando como apoderado de la sociedad, **GENENTECH, INC.**, según lo acredita el documento de poder presentado en esa División, para dar cumplimiento al requerimiento notificado por fijación en lista el 23 de enero de 2009, de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la comisión de la Comunidad Andina, me permito allegar:

1. Documentos (4) donde consta la cesión del derecho a la patente otorgado por el inventor al solicitante, debidamente apostillados, junto con sus correspondientes traducciones al castellano.
2. Copia del Reporte Preliminar Internacional sobre la Patentabilidad (Formas PCT/IB/373 y PCT/ISA/237).
3. Extracto para publicación y Tarjeta de archivo temático.

De la señora Jefe atentamente,


JUAN PABLO CADENA SARMIENTO
C.C. No. 80.410.337 de Usaquén
Cra 7 No. 71-21, Torre B, Piso 4

Bogotá, 18 de marzo de 2009
CHP/MXB/jpg

(21) N° de solicitud: 08 129.885 (22) Fecha de solicitud: 05-12-2008

(541) Clasificación Internacional:

(71) Solicitante(s): **GENENTECH, INC.**

(72) Inventor(es): Minhong YAN, Yan WU.

(74) Agente: JUAN PABLO CADENA SARMIENTO

(30) Prioridad	(31)	No. Prioridad	(32)	Fecha	(33)	País
		60/811,349		06-06-2006		US
		60/811,357		06-06-2006		US
		60/866,772		21-11-2006		US
		60/866,767		21-11-2006		US

FIGURA CARACTERISTICA
 6 x 6 cm

(85) Fecha inicio fase nacional: 06-01-2009

(86) Datos relativos a la presentación de la solíc. PCT
 Fecha de presentación de la solicitud: 06-06-2007
 No. de solicitud: PCT/US2007/070513

(87) Publicación internacional:

Fecha: 22-05-2008
 No. Publicación: WO/2008/060705 A 2

(54) Título: **ANTICUERPOS ANTI-DLL4 Y MÉTODOS QUE LOS USAN.**

(57) Resumen

Anticuerpos anti-DLL4, composiciones que comprenden estos anticuerpos y métodos de uso de los mismos.

CONTINUA AL RESPALDO ...

 Industria y Comercio SUPERINTENDENCIA		SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO DIVISION DE NUEVAS CREACIONES EXTRACTO PARA PUBLICACIÓN SOLICITUD DE PATENTE DE INVENCION PCT	
(21) N° de solicitud: 08 129.885		(51) Int Cl:	
(22) Fecha de solicitud: 05-12-2008		(71) Solicitante(s) GENENTECH, INC.	
(30) Prioridad	(31) No. Prioridad	(32) Fecha	(33) Pais
	60/811,349	06-06-2006	US
	60/811,357	06-06-2006	US
	60/866,772	21-11-2006	US
	60/866,767	21-11-2006	US
(85) Fecha inicio fase nacional: 06-01-2009		(72) Inventor(es) Minhong YAN, Yan WU.	
(86) Datos relativos a la presentación de la solicitud PCT		(74) Agente: JUAN PABLO CADENA SARMIENTO	
Fecha de presentación de la solicitud: 06-06-2007		(87) Publicación internacional	
No. de solicitud: PCT/US2007/070513		Fecha: 22-05-2008	
		N° publicación: WO/2008/060705A 2	
(54) Título: ANTICUERPOS ANTI-DLL4 Y MÉTODOS QUE LOS USAN.			

(57) Resumen

Anticuerpos anti-DLL4, composiciones que comprenden estos anticuerpos y métodos de uso de los mismos.

From the INTERNATIONAL BUREAU

PCT**NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)**

(PCT Rule 44bis.1(c))

To:

KALINOWSKI, Grant
Genentech, Inc.
1 DNA Way, MS-49
South San Francisco, California 94080
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

24 December 2008 (24.12.2008)

Applicant's or agent's file reference

P2336R1 WO

IMPORTANT NOTICE

International application No.

PCT/US2007/070513

International filing date (day/month/year)

06 June 2007 (06.06.2007)

Priority date (day/month/year)

06 June 2006 (06.06.2006)

Applicant

GENENTECH, INC. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

RECEIVED

JAN 15 2009

GENENTECH, INC.
LEGAL DEPT.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Ellen Moyse

Facsimile No. +41 22 338 82 70

e-mail: nlr.pcr@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference P2336R1 WO	FOR FURTHER ACTION		See item 4 below
International application No. PCT/US2007/070513	International filing date (day/month/year) 06 June 2007 (06.06.2007)	Priority date (day/month/year) 06 June 2006 (06.06.2006)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant GENENTECH, INC.			

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).		
2.	This REPORT consists of a total of 10 sheets, including this cover sheet.		
In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.			
3.	This report contains indications relating to the following items:		
☒	Box No. I	Basis of the report	
☒	Box No. II	Priority	
☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
☐	Box No. IV	Lack of unity of invention	
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	
☒	Box No. VI	Certain documents cited	
☐	Box No. VII	Certain defects in the international application	
☐	Box No. VIII	Certain observations on the international application	
4.	The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 82 70	Date of issuance of this report 10 December 2008 (10.12.2008)
	Authorized officer Ellen Moyse e-mail: pr02.pct@wipo.int

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

see form PCT/ISA/220

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY
(PCT Rule 43bis.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION
See paragraph 2 below

International application No.
PCT/US2007/070513

International filing date (day/month/year)
06.06.2007

Priority date (day/month/year)
06.06.2006

International Patent Classification (IPC) or both national classification and IPC
INV. C07K16/22 C12N15/13 C12N5/12 A61K39/395 A61P35/00

Applicant
GENENTECH, INC.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☒ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☒ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Date of completion of
this opinion

see form
PCT/ISA/210

Authorized Officer

Ferreira, Roger

Telephone No. +49 89 2399-2711



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2007/070513

Box No. I Basis of the opinion

1. With regard to the language, this opinion has been established on the basis of:
 - ☒ the international application in the language in which it was filed
 - ☐ a translation of the international application into , which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1 (b)).
2. ☐ This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material:
 - ☒ on paper
 - ☒ in electronic form
 - c. time of filing/furnishing:
 - ☒ contained in the international application as filed.
 - ☒ filed together with the international application in electronic form.
 - ☐ furnished subsequently to this Authority for the purposes of search.
4. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2007/070513

Box No. II Priority

1. ☒ The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.
2. ☐ This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
3. Additional observations, if necessary:
see separate sheet

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	<u>1-27,29-43</u>
	No: Claims	<u>28</u>
Inventive step (IS)	Yes: Claims	
	No: Claims	<u>1-43</u>
Industrial applicability (IA)	Yes: Claims	<u>1-43</u>
	No: Claims	

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rules 43bis.1 and 70.10)

and/or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2007/070513

Reference is made to the following documents:

- D1: LIU ZHAO-JUN ET AL: "Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1." THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY MAY 2006, vol. 20, no. 7, May 2006 (2006-05), pages 1009-1011, XP002491745 ISSN: 1530-6860
- D2: NOGUERA IRENE ET AL: "Delta-like ligand 4 (Dll4) is critical for tumor growth and angiogenesis." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 47, April 2006 (2006-04), page 1342, XP001537721 & 97TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01 -05, 2006 ISSN: 0197-016X
- D3: PATEL NILAY S ET AL: "Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 65, no. 19, October 2005 (2005-10), pages 8690-8697, XP002452160 ISSN: 0008-5472 cited in the application
- D4: WO 2005/012359 A (GENENTECH INC [US]; FUH GERMAINE [US]; GERBER HANSPETER [US]; LIANG WE) 10 February 2005 (2005-02-10) cited in the application
- D5: HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484-490, XP004467495 ISSN: 0167-7799
- D6: DAVIES J ET AL: "Affinity Improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169-179, XP004070292 ISSN: 1380-2933

Subject-matter of the application

The present application relates to an isolated anti-DLL4 antibody comprising at least one hypervariable region (HVR) sequence, wherein HVR-L1 comprises a sequence as set forth in SEQ ID NO:10, HVR-L2 in SEQ ID NO:11, HVR-L3 in one of SEQ ID NOs:12-18, HVR-H1 in one of SEQ ID NOs:1 and 2, HVR-H2 in one of SEQ ID NOs:3-8, and HVR-H3 in SEQ ID NO:9. A polynucleotide encoding said antibody, a vector comprising said polynucleotide, a host cell comprising said vector and a method for making said antibody by use of said host cell are also claimed. The present application also relates to the use of said antibody in therapeutic applications.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2007/070513

Re Item II

1. Priority, Rules 43bis.1 and 64.1 PCT

This preliminary opinion is being established under the assumption that the entire subject-matter is entitled to the claimed priority. If this is not the case, the "P/X" documents cited in the search report may have to be considered for novelty and inventive step, and the "E" document for novelty.

Re Item V

1. Novelty, Article 33(2) PCT

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 28 is not new in the sense of Article 33(2) PCT.

1.1 D1 discloses (see abstract, page E203 right-hand column fourth paragraph, paragraph bridging pages E203 and E204, figure 1 of the Full-Length Article) a method for detection of DLL4 in a biological sample by use of an anti-DLL4 antibody. D1 thus anticipates the subject-matter of claim 28.

1.2 Claims 1-27 and 29-43 appear to be novel in view of the documents cited in the International Search Report.

2. Sufficiency of disclosure, Support and Inventive step, Article 5, 6 and 33(3) PCT

2.1 As far as the claims employ antibodies only characterized by part of their sequence (e.g. only some of the CDRs or various combinations of CDRs, as well as various variants thereof) the claims do not fulfill the requirements of Articles 5, 6 and 33(3) PCT:

The present application only discloses antibodies comprising specific VL and VH regions (see, for example, figure 6).

It is well established in the art that the formation of an intact antigen-binding site as well as the maintenance of the antigen-binding specificity and affinity critically depends on the amino acid sequence and conformations of each CDRs of the light and heavy chains.

It is further expected that all CDRs in the proper order and in the context of the framework sequences which maintain their required conformation, are required to produce a polypeptide having functional antigen-binding sites. D5, for example, discloses (see, e.g. abstract) that a single CDR is not sufficient to give rise to a functional antibody molecule.

As can be seen from, e.g. D4, the presence of the identical CDR1, CDR2 and CDR3 sequences of the light chain of the antibodies of the present application in the context of different CDRs sequences of the heavy chain results in an antibody with a different specificity

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2007/070513

(i.e. an antibody which specifically binds VEGF). Indeed, D4 discloses (see claim 50) an anti-VEGF antibody which comprises a VL having CDR1, CDR2 and CDR3 sequences which share 100% identity with SEQ ID NOs:10, 11 and 12, respectively. Accordingly, it is unlikely that all the antibodies encompassed by the present claims have the required function and thus solve the problem of the invention (Article 33(3) PCT). Moreover, it is not sufficient to characterize an antibody by one or two of the CDR sequences (or various combinations or variants thereof) since antigen-binding specificity depends on all three CDRs and four framework regions (which hold said CDRs in the correct conformation) of each of the heavy and light chains (i.e. 6 CDRs in total). The specification of one CDR in the absence of the other CDR sequences or various combinations of different CDR sequences or variants thereof is therefore unlikely to provide all essential features of the antibody (Article 5 PCT). D6, for example, teaches (see, e.g. abstract and discussion) that all three CDRs of camelised VH are responsible for affinity and antigen-binding. Moreover, D5 teaches (see, e.g. pages 485-486 under "Biological properties") that due to aggregation, low expression level and low stability, the generation of only VL or VH is not possible as long as they are not camelised. Since there is no teaching in the present application of how to obtain such VL or VH sequences from the disclosed antibodies, the claims concerned lack support (Article 6 PCT).

As a consequence, claims 1-5, 11-16 and 31-33 are not considered to meet the requirements of Articles 5, 6 and 33(3) PCT.

- 2.2 The same reasoning as given above under Re Item V.2.1 applies *mutatis mutandis* to claims 17-27, relating to nucleic acids encoding said antibodies, vectors and host cells and their use for the production of said antibodies, which is common practice.

The subject-matter of claims 17-27 is, therefore, not considered to involve an inventive step (Article 33(3) PCT).

- 2.3 The subject-matter of claims 6-10 is not considered to involve an inventive step for the following reasons:

D2, which may be regarded as the closest prior art with regard to the subject-matter of the present application, discloses (see abstract) the use of a DLL4 antagonist (i.e. a soluble DLL4-Fc molecule) for blocking DLL4 function in tumors. D2 further teaches that DLL4 is a protein encoded by a VEGF-regulated gene, and therefore may be an attractive potential target for the development of anti-angiogenic therapies. In addition, D3 discloses (see

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2007/070513

abstract, page 8693 left-hand column second full paragraph to page 8695 left-hand column second paragraph, discussion, figures 2-6) that down-regulation of DLL4 (a VEGF-regulated protein) expression using RNA interference leads to the inhibition of endothelial cell proliferation, migration and network formation, all of which are important processes in tumor angiogenesis. D3 further teaches that an optimal window of the DLL4 expression is essential for tumor angiogenesis and that selective modulation of DLL4 within tumors may represent a potential anti-angiogenic therapy.

The subject-matter of the present application differs from the disclosure of D2 in that the antagonists used for blocking DLL4 function in tumors are anti-DLL4 neutralizing antibodies.

In absence of apparent surprising technical effect relating to the use of said antibodies, the problem to be solved by the present application might be considered as the provision of additional DLL4 antagonists in order to treat tumors.

D4 discloses (see abstract, claims 1-69) the use of anti-VEGF neutralizing antibodies as anti-angiogenic agents for treating tumors.

For the skilled person, therefore, starting from the disclosure of D2 and D3, which relate to the fact that DLL4 expression is regulated by VEGF (a protein well-known in the art as being implicated in tumor angiogenesis) and that specific inhibition of DLL4 function is very likely to represent an anti-angiogenic therapy, and aware of the disclosure of D4, which refers to anti-VEGF-neutralizing antibodies and their use in treating tumor angiogenesis, it would be obvious to use the same methods for producing antibodies as the ones disclosed in D4 (i.e. through generation of synthetic phage antibody libraries built on humanized anti-ErbB2 antibody, 4D5, framework, as used in the present application) in order to design and generate anti-DLL4 neutralizing antibodies to provide additional DLL4 antagonists for treating tumors. The selection of a particular anti-DLL4 neutralizing antibody without assigned function (i.e. an anti-DLL4 antibody comprising HVR-L1 of SEQ ID NO:10, HVR-L2 of SEQ ID NO:11, HVR-L3 of one of SEQ ID NOs:14-18, HVR-H1 of one of SEQ ID NOs:1 and 2, HVR-H2 of one of SEQ ID NOs:3 and 5-8, and HVR-H3 of SEQ ID NO:9, according to claims 6-10) from a group of anti-DLL4 neutralizing antibodies is considered arbitrary.

Therefore, the subject-matter of claims 6-10 is not considered to involve an inventive step in the sense of Article 33(3) PCT.

7

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/US2007/070513

- 2.4 The same reasoning as given above under Re Item V.2.3 applies *mutatis mutandis* to the subject-matter of claims 29-30 and 34-43. Indeed, D4 also discloses (see abstract, claims 1-69) methods for diagnosing and/or treating a tumor by use of said anti-VEGF neutralizing antibodies.

Claims 29-30 and 34-43 are thus not considered to fulfil the requirements of Article 33(3) PCT for lack of inventive step of their subject-matter.

3. Remark concerning claims 28-30 and 34-43

The patentability can be dependent upon the formulation of the claims. The EPO, for example, does not recognize as patentable claims to the use of a compound in medical treatment, but may allow claims to a product, in particular substances or compositions for use in a first or further medical treatment.

4. General remark

The claims have been considered to relate to anti-DLL4-antibodies comprising at least one HVR, wherein said HVR comprises a sequence as set forth in one of SEQ ID NOs:1-18, to methods of producing said antibodies, and to methods for diagnosing and/or treating tumors by use of said antibodies. In addition, the examples of the present application disclose said methods only in the context of said specific anti-DLL4 antibodies. However, present claims 28-30 relate to methods for detecting DLL4 and for diagnosing a disorder associated with DLL4 expression by use of anti-DLL4 antibodies which are not limited to the ones disclosed and exemplified in the present application (indeed these claims relate to any anti-DLL4 antibody). Due to the disclosure of D1 (which discloses a method for detection of DLL4 in a biological sample by use of an anti-DLL4 antibody (see abstract, page E203 right-hand column fourth paragraph, paragraph bridging pages E203 and E204, figure 1 of the Full-Length Article)), the subject-matter of claims 28, 29 and 30 might not be considered to be linked by a single general inventive concept to the subject-matter of claims 1-27 and 31-43.

Re Item VI

1. Certain published documents

- D7: RIDGWAY JOHN ET AL: "Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis" NATURE (LONDON), vol. 444, no. 7122, December 2006 (2006-12), pages 1083-1087, XP002457725-ISSN: 0028-0836
- D8: NOGUERA-TROISE IRENE ET AL: "Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis" NATURE (LONDON), vol. 444, no. 7122, December 2006

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)

International application No.

PCT/US2007/070513

(2006-12), pages 1032-1037, XP002457724 ISSN: 0028-0836

D9: LOBOV I B ET AL: "Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 9, February 2007 (2007-02), pages 3219-3224, XP002457726 ISSN: 0027-8424.

D10: US 2006/134121 A1 (THURSTON GAVIN [US] ET AL) 22 June 2006 (2006-06-22)

D11: WO 2007/028110 A (VASGENE THERAPEUTICS INC [US]; GILL PARKASH [US]; DUARTE, ANTONIO [PT]); 8 March 2007 (2007-03-08)

D12: WO 2007/070671 A (REGENERON PHARMA [US]; NOGUERA IRENE [US]; THURSTON GAVIN [US]; GALE N) 21 June 2007 (2007-06-21) (E)

40

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*

This public document

2. has been signed by T. Lawrence

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U.S. Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the twenty-eighth of November, 2008

7. by *Assistant Authentication Officer, United States Department of State*

8. No. 09006307-9


9. Seal/Stamp:

10. Signature:



Patrick O. Hatchett

A 7156699



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

November 14, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
DECEMBER 18, 2006.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



T. LAWRENCE
Certifying Officer

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Minhong Yan	12/04/2006
RECEIVING PARTY DATA	
Name:	Genentech, Inc.
Street Address:	1 DNA Way
Internal Address:	MS-49
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	60866767
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650 467 2607
Email:	pgolden@gene.com
Correspondent Name:	Grant Kalinowski
Address Line 1:	1 DNA Way
Address Line 2:	MS-49
Address Line 4:	South San Francisco, CALIFORNIA 94080
NAME OF SUBMITTER:	Grant Kalinowski
Total Attachments: 2 source=PR2372#page1.tif source=PR2372#page2.tif	

CH \$40.00 60866767

500195621

PATENT
REEL: 018648 FRAME: 0732

cl

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

Commissioner for Patents: Please record the attached original documents or copy thereof.

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

Atty Dkt No: **PR-2372-1**

1. Name of conveying party(ies):

Minhong Yan, Foster City, CA

Additional name(s) of conveying party(ies) attached? _ Yes ☒ No

2. Name and address of receiving party(ies):

Name: GENENTECH, INC.

Internal Address:

Street Address: 1 DNA Way

City: South San Francisco State: California

ZIP: 94080-4990

Additional name(s) & address(es) attached? _ Yes ☒ No

3. Nature of conveyance:

☒ Assignment

Merger

Security Agreement

Change of Name

Other:

Execution Date: 04-DEC-2006

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 60/866,767

B. Patent No.(s)

Additional numbers attached? _ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Grant Kalinowski
GENENTECH, INC.
1 DNA Way
South San Francisco, CA 94080

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$ 40.00

_ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number:

07-0630

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Grant Kalinowski

Name of Person Signing
Registration No. 48,314



Signature

12/18/06

Date

Total number of pages comprising cover sheet, attachments and document: 2

Revised (10/11/93)

#229780

**PATENT
REEL: 018648 FRAME: 0733**

ASSIGNMENT

WHEREAS, Minhong Yan, a citizen of the USA residing at 411 Nantucket Street, Foster City, CA 94404 (hereinafter "ASSIGNOR"), has invented a new and useful invention in

COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT

for which a provisional application Serial No. 60/866,767, (Docket No. PR2372-1) has been filed on 21-NOV-2006; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNOR has and does hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNOR covenants and agrees to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNOR includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNOR in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNOR, his/her respective heirs, legal representatives and assigns.

Said ASSIGNOR hereby warrants and represents that he/she has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.


IN WITNESS WHEREOF I undersign as follows;

South San Francisco:

Date

12/18/2006


Name: Minhong Yan



#228122

RECORDED: 12/18/2006

PATENT
REEL: 018648 FRAME: 0734



TRADUCCIÓN AL ESPAÑOL DEL DOCUMENTO DE CESIÓN A
GENENTECH, INC firmado por los cedentes y el cesionario.

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)

1. País: Estados Unidos de América

Este documento público

- 2. ha sido firmado por T. Lawrence
- 3. actuando en capacidad de Funcionario que Certifica
- 4. lleva el sello/timbre de la Oficina de Marcas y Patentes de E.U.

Certificado

- 5. en Washington, D.C.
- 6. el veintiocho de noviembre de 2008
- 7. por el Funcionario de Autenticación Asistente, Departamento de Estado de los Estados Unidos.
- 8. No. 09006307-9
- 9. Sello/timbre

10. Firma

(Firma)
Patrick O. Hatchett

[Sello]



LOS ESTADOS UNIDOS DE AMÉRICA
A TODO AQUEL QUE PUEDA LLEGAR LA PRESENTE:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS
Oficina de Marcas y Patentes

14 de Noviembre 2008

LA PRESENTE CERTIFICA QUE EL ANEXO ES UNA COPIA VERDADERA
DE LOS ARCHIVOS DE ESTA OFICINA DE UN DOCUMENTO
ARCHIVADO EL 18 DE DICIEMBRE DE 2006.

Por la autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Marcas y Patentes de los Estados Unidos

(Firma)
T. LAWRENCE
Funcionario que certifica

Hay un sello que dice:
Oficina de Marcas y Patentes de Estados Unidos
Departamento de Comercio

29

CESIÓN DE PATENTE	
Versión electrónica v1.1	
Versión de la hoja v1.1	
TIPO DE PRESENTACIÓN:	CESIÓN NUEVA
NATURALEZA DEL ACUERDO:	CESIÓN
DATOS DE LA PARTE CEDENTE	
Nombre	Fecha de ejecución
Minhong Yang	12/04/2006
DATOS DE LA PARTE QUE RECIBE	
Nombre:	Genentech, Inc.
Dirección:	1 DNA Way
Dirección Interna:	MS-49
Ciudad:	South San Francisco
Estado/País:	CALIFORNIA
Código Postal:	94080
NÚMERO DE PROPIETARIOS Total: 1	
Tipo de Propiedad	Número
Número de solicitud:	60866767
DATOS DE CORRESPONDENCIA	
Número de Fax:	(650)952-9881
<i>La correspondencia será enviada por Correo de Estados Unidos cuando los intentos de hacerlo por fax no sean exitosos.</i>	
Teléfono:	650 467 2607
Correo electrónico:	pgolden@gene.com
Nombre del destinatario:	Grant Kalinowski
Dirección Línea 1:	1 DNA Way
Dirección Línea 2:	MS-49
Dirección Línea 4:	South San Francisco, CALIFORNIA 94080
NOMBRE DEL REMITENTE:	Grant Kalinowski
Anexos totales:2	
Fuente=PR2372#page1.tif	
Fuente=PR2372#page2.tif	

HOJA DE PORTADA DEL FORMULARIO DE
REGISTRO
SOLAMENTE PATENTES

Departamento de Comercio de
Estados Unidos
Oficina de Marcas y Patentes
Expediente de abogado No. PR-
2372-1

Comisionado para Patentes: Por favor archive los documentos originales anexos o
copia de los mismos

1. Nombre de la(s) parte(s) cedente(s): Minhong Yan, Foster City, CA ¿Se anexa(n) nombre(s) adicional(es) de la parte(s) cedente(s)? Si ☒ No ☐	2. Nombre y dirección de la(s) parte(s) receptora(s) Nombre: <u>GENENTECH, INC.</u> Dirección Interna: Dirección: <u>1 DNA Way</u> Ciudad: <u>South San Francisco</u> Estado: <u>California</u> Código Postal: <u>94080-4990</u> ¿Se anexan nombre(s) y dirección(es) adicional(es)? Si ☐ No ☒
3. Naturaleza del traspaso: [X] Cesión Acuerdo de Seguridad Cambio de Nombre Otro: Fusión	
4. Numero(s) de solicitud o número(s) de patente: Si este documento se presenta junto con una nueva solicitud, la fecha de ejecución de la solicitud es: A. Solicitud de patente No(s). 60/866,767 B. Patente No(s). ¿Se anexan números adicionales? Si ☐ No ☒	
5. Nombre y dirección de la parte a quien se le debe enviar la correspondencia: Grant Kalinowski GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080	6. Numero total de solicitudes y patentes involucradas: <u>1</u> 7. Tarifa total (37 C.F.R 3.41): <u>\$40.00</u> ☐ Anexo ☒ Autorizado a ser cargado a una cuenta de ahorros 8. Número de cuenta de ahorros: <u>07-0630</u>
NO USE ESTE ESPACIO	
9. Declaración y firma. Hasta donde sé y creo, la información anterior es verdadera y correcta y cualquier copia anexa es una copia verdadera del documento original. Grant Kalinowski Nombre de la persona que firma Registro No. 48,314 (Firma) Firma 18 de diciembre de 2006 Fecha	
Número total de páginas que comprenden portada, anexos y documento: 2	

24

Expediente de Abogado No. PR2372-1

CESIÓN

CONSIDERANDO QUE, **Minhong Yang**, un ciudadano de los E.U.A., residente en **411 Nantucket Street, Foster City, CA 94404**, (en adelante denominado como "CEDENTE"), ha inventado una invención nueva y útil

COMPOSICIONES Y MÉTODOS PARA LA MODULACIÓN DEL DESARROLLO VASCULAR

para la cual se presentó una solicitud provisional con Serie No. 60/866,767 (Expediente No. PR2372-1) por ella el 21 de noviembre de 2006; y

CONSIDERANDO QUE, GENENTECH, INC., una corporación organizada y existente bajo y por virtud de las leyes del Estado de Delaware, que tiene oficinas en 1 DNA Way, South San Francisco, California 94080-4990, está deseosa de adquirir un interés en y para dicha invención, y en y para las patentes que se obtendrán de la misma;

AHORA, POR LO TANTO, téngase por sabido por todo aquel que le concierna:

Que por una consideración buena y valiosa el recibo de la cual se reconoce por la presente, dicho CEDENTE ha y por la presente vende, cede, transfiere y traspasa a dicha GENENTECH, INC. sus sucesores y cesionarios, el derecho, título e interés completo y exclusivo incluyendo todos los derechos bajo la Convención de Paris para la Protección de la Propiedad Industrial, en y para dicha invención, y en y para cualquiera y todas las patentes que se concedan y emitan para la misma o cualquier continuación, división, renovación, o sustitución de la misma, y en cuanto a patentes cualquier reemisión o reexaminación de las mismas, no solo para, por y en los Estados Unidos de América, sus territorios y posesiones, sin para, por y en todos los otros países; y se ha y por la presente se autoriza y solicita que las agencias gubernamentales respectivas emitan dichas patentes a GENENTECH, INC. de acuerdo con esta cesión.

Dicho CEDENTE garantiza y acuerdan cooperar con GENENTECH, INC., para posibilitar a dicha GENENTECH, INC., a disfrutar hasta su máxima extensión el derecho, título e interés aquí cedido en Estados Unidos y los países extranjeros. Tal cooperación por dicho CEDENTE incluye la pronta producción de hechos y documentos pertinentes, dando testimonio, ejecutando peticiones, juramentos, especificaciones, declaraciones u otros documentos, y otra ayuda todas hasta el punto considerado necesario o deseable por dichas GENENTECH, INC. (a) para perfeccionar el derecho, título e interés aquí cedido; (b) para procesar cualquiera de dichas solicitudes; (c) para presentar y procesar solicitudes de reemisión de cualquiera de dichas patentes; (d) para procesos de interferencia u otros procesos de prioridad que involucren dicha invención; y (e) para procedimientos legales que involucren dicha invención y cualquier solicitud de la misma y cualquier patente concedida sobre la misma, incluyendo sin limitación procedimientos de oposición, procedimientos de cancelación, disputas de prioridad, procesos de uso público, acciones de violación y acciones de la corte; con la condición que los gastos incurridos por dicho CEDENTE al proporcionar dicha cooperación deban ser pagados por GENENTECH, INC.

Los términos y garantías de esta cesión deben actuar en beneficio de dicha GENENTECH, INC. sus sucesores, cesionarios y otros representantes legales, y deberá ser obligante sobre dicho CEDENTE, sus respectivos herederos, representantes legales y cesionarios.

Dicho CEDENTE por la presente garantiza y manifiesta que no ha entrado y no entrará en ninguna cesión, contrato o entendimiento en conflicto con la presente.

EN TESTIMONIO DE LO CUAL se suscribe como sigue:

South San Francisco
Diciembre 4, 2006
Fecha
#228122

ARCHIVADO: 12/18/2006

(firma)
Nombre: Minhong Yan

PATENTE
ROLLO: 018648 CUADRO: 0734

AS:108822

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document

2. has been signed by T. Lawrence

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U.S. Patent and Trademark Office

Certified

5. at Washington, D.C.


6. the twenty-eighth of November, 2008

7. by Assistant Authentication Officer, United States Department of State

8. No. 09006307-12

9. Seal/Stamp:

10. Signature:


Patrick O. Hatchett

A 7156699

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

November 14, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
JULY 5, 2006.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

T. Lawrence

T. LAWRENCE
Certifying Officer



PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Minhong Yan	06/30/2006
RECEIVING PARTY DATA	
Name:	Genentech, Inc.
Street Address:	1 DNA Way
Internal Address:	MS-49
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94090
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	60811357
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6504676222
Email:	pgolden@gene.com
Correspondent Name:	Cara M. Coburn
Address Line 1:	1 DNA Way
Address Line 2:	MS-49
Address Line 4:	South San Francisco, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	PR2372
NAME OF SUBMITTER:	Cara M. Coburn
Total Attachments: 1 source=assignment#page1.tif	

CH \$40.00 60811357

500122643

PATENT
REEL: 017880 FRAME: 0053

ASSIGNMENT

WHEREAS, Minhong Yan, a citizen of the USA residing at 411 Nantucket Street, Foster City, CA 94404 (hereinafter "ASSIGNOR"), has invented a new and useful invention in

COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT

for which a provisional application Serial No. 60/811,357, (Docket No. PR2372) has been filed on June 6, 2006; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNOR has and does hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNOR covenants and agrees to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNOR includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNOR in providing such cooperation shall be paid for by said GENENTECH, INC..

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNOR, his/her respective heirs, legal representatives and assigns.

Said ASSIGNOR hereby warrants and represents that he/she has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.


IN WITNESS WHEREOF I undersign as follows;

South San Francisco:

Date

6-30-2006

Name: Minhong Yan



#213963

RECORDED: 07/05/2006

PATENT
REEL: 017880 FRAME: 0054

37

TRADUCCIÓN AL ESPAÑOL DEL DOCUMENTO DE CESIÓN A
GENENTECH, INC firmado por los cedentes y el cesionario.

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)

1. País: Estados Unidos de América

Este documento público

- 2. ha sido firmado por T. Lawrence
- 3. actuando en capacidad de Funcionario que Certifica
- 4. lleva el sello/timbre de la Oficina de Marcas y Patentes de E.U.

Certificado

- 5. en Washington, D.C.
- 6. el veintiocho de noviembre de 2008
- 7. por el Funcionario de Autenticación Asistente, Departamento de Estado de los Estados Unidos.
- 8. No. 09006307-12
- 9. Sello/timbre

10. Firma

(Firma)
Patrick O. Hatchett

[Sello]

34

LOS ESTADOS UNIDOS DE AMÉRICA
A TODO AQUEL QUE PUEDA LLEGAR LA PRESENTE:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS
Oficina de Marcas y Patentes

14 de Noviembre 2008

LA PRESENTE CERTIFICA QUE EL ANEXO ES UNA COPIA VERDADERA
DE LOS ARCHIVOS DE ESTA OFICINA DE UN DOCUMENTO
ARCHIVADO EL 5 DE JULIO DE 2006.

Por la autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Marcas y Patentes de los Estados Unidos

(Firma)
T. LAWRENCE
Funcionario que certifica

Hay un sello que dice:
Oficina de Marcas y Patentes de Estados Unidos
Departamento de Comercio

21

CESIÓN DE PATENTE	
Versión electrónica v1.1	
Versión de la hoja v1.1	
TIPO DE PRESENTACIÓN:	CESIÓN NUEVA
NATURALEZA DEL ACUERDO:	CESIÓN
DATOS DE LA PARTE CEDENTE	
Nombre	Fecha de ejecución
Minhong Yang	30/06/2006
DATOS DE LA PARTE QUE RECIBE	
Nombre:	Genentech, Inc.
Dirección:	1 DNA Way
Dirección Interna:	MS-49
Ciudad:	South San Francisco
Estado/País:	CALIFORNIA
Código Postal:	94080
NÚMERO DE PROPIETARIOS Total: 1	
Tipo de Propiedad	Número
Número de solicitud:	60811357
DATOS DE CORRESPONDENCIA	
Número de Fax:	(650)952-9881
<i>La correspondencia será enviada por Correo de Estados Unidos cuando los intentos de hacerlo por fax no sean exitosos.</i>	
Teléfono:	650 467 6222
Correo electrónico:	pgolden@gene.com
Nombre del destinatario:	Cara M. Coburn
Dirección Línea 1:	1 DNA Way
Dirección Línea 2:	MS-49
Dirección Línea 4:	South San Francisco, CALIFORNIA 94080
NÚMERO DE EXPEDIENTE DE ABOGADO:	PR2372
NOMBRE DEL REMITENTE:	Cara M. Coburn
Anexos totales:1	
Fuente=assignment#page1.tif	

CESIÓN

CONSIDERANDO QUE, Minhong Yang, un ciudadano de los E.U.A., residente en 411 Nantucket Street, Foster City, CA 94404, (en adelante denominado como "CEDENTE"), ha inventado una invención nueva y útil

COMPOSICIONES Y MÉTODO PARA MODULACIÓN DEL DESARROLLO VASCULAR

para la cual se presentó una solicitud provisional con Serie No. 60/811,357 (Expediente No. PR2372) por ella el 6 de junio de 2006; y

CONSIDERANDO QUE, GENENTECH, INC., una corporación organizada y existente bajo y por virtud de las leyes del Estado de Delaware, que tiene oficinas en 1 DNA Way, South San Francisco, California 94080-4990, está deseosa de adquirir un interés en y para dicha invención, y en y para las patentes que se obtendrán de la misma;

AHORA, POR LO TANTO, téngase por sabido por todo aquel que le concierna:

Que por una consideración buena y valiosa el recibo de la cual se reconoce por la presente, dicho CEDENTE ha y por la presente vende, cede, transfiere y traspasa a dicha GENENTECH, INC. sus sucesores y cesionarios, el derecho, título e interés completo y exclusivo incluyendo todos los derechos bajo la Convención de Paris para la Protección de la Propiedad Industrial, en y para dicha invención, y en y para cualquiera y todas las patentes que se concedan y emitan para la misma o cualquier continuación, división, renovación, o sustitución de la misma, y en cuanto a patentes cualquier reemisión o reexaminación de las mismas, no solo para, por y en los Estados Unidos de América, sus territorios y posesiones, sin para, por y en todos los otros países; y se ha y por la presente se autoriza y solicita que las agencias gubernamentales respectivas emitan dichas patentes a GENENTECH, INC. de acuerdo con esta cesión.

Dicho CEDENTE garantiza y acuerda cooperar con GENENTECH, INC., para posibilitar a dicha GENENTECH, INC., a disfrutar hasta su máxima extensión el derecho, título e interés aquí cedido en Estados Unidos y los países extranjeros. Tal cooperación por dichos CEDENTES incluye la pronta producción de hechos y documentos pertinentes, dando testimonio, ejecutando peticiones, juramentos, especificaciones, declaraciones u otros documentos, y otra ayuda todas hasta el punto considerado necesario o deseable por dichas GENENTECH, INC. (a) para perfeccionar el derecho, título e interés aquí cedido; (b) para procesar cualquiera de dichas solicitudes; (c) para presentar y procesar solicitudes de reemisión de cualquiera de dichas patentes; (d) para procesos de interferencia u otros procesos de prioridad que involucren dicha invención; y (e) para procedimientos legales que involucren dicha invención y cualquier solicitud de la misma y cualquier patente concedida sobre la misma, incluyendo sin limitación procedimientos de oposición, procedimientos de cancelación, disputas de prioridad, procesos de uso público, acciones de violación y acciones de la corte; con la condición que los gastos incurridos por dicho CEDENTE al proporcionar dicha cooperación deban ser pagados por GENENTECH, INC.

Los términos y garantías de esta cesión deben actuar en beneficio de dicha GENENTECH, INC. sus sucesores, cesionarios y otros representantes legales, y deberá ser obligante sobre dicho CEDENTE, sus respectivos herederos, representantes legales y cesionarios.

Dicho CEDENTE por la presente garantiza y manifiesta que no ha entrado y no entrará en ninguna cesión, contrato o entendimiento en conflicto con la presente.

EN TESTIMONIO DE LO CUAL se suscribe como sigue:

South San Francisco
Junio 30, 2006
Fecha

(firma)
Nombre: Minhong Yan

ARCHIVADO: 07/05/2006

PATENTE
ROLLO: 017880 CUADRO: 0054

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document

2. has been signed by T. Lawrence

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U.S. Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the twenty-eighth of November, 2008

7. by Assistant Authentication Officer, United States Department of State

8. No. 09006307-14

9. Seal/Stamp:

10. Signature:



Patrick O. Hatchett

A 7156699

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

November 14, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
JULY 7, 2006.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



T. Lawrence

T. LAWRENCE
Certifying Officer

10

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="text-align: center; padding: 5px;">Name</th> <th style="text-align: center; padding: 5px;">Execution Date</th> </tr> <tr> <td style="padding: 5px;">Minhong Yan</td> <td style="padding: 5px;">07/05/2006</td> </tr> <tr> <td style="padding: 5px;">Yan Wu</td> <td style="padding: 5px;">07/05/2006</td> </tr> </table>	Name	Execution Date	Minhong Yan	07/05/2006	Yan Wu	07/05/2006	
Name	Execution Date						
Minhong Yan	07/05/2006						
Yan Wu	07/05/2006						

RECEIVING PARTY DATA	
Name:	Genentech, Inc.
Street Address:	1 DNA Way
Internal Address:	MS-49
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080

PROPERTY NUMBERS Total: 1					
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="text-align: center; padding: 5px;">Property Type</th> <th style="text-align: center; padding: 5px;">Number</th> </tr> <tr> <td style="padding: 5px;">Application Number:</td> <td style="padding: 5px;">60811349</td> </tr> </table>	Property Type	Number	Application Number:	60811349	
Property Type	Number				
Application Number:	60811349				

CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650 467 6222
Email:	pgolden@gene.com
Correspondent Name:	Cara M. Coburn
Address Line 1:	1 DNA Way
Address Line 2:	MS-49
Address Line 4:	South San Francisco, CALIFORNIA 94080

ATTORNEY DOCKET NUMBER:	PR2336
NAME OF SUBMITTER:	Cara M. Coburn

Total Attachments: 3
 source=assignment- 07-07-06 - LYS2LEJ#page1.tif

CH \$40.00 60811349

C/4

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco

Date

Name: Minhong Yan

South San Francisco

Date

7-5-2006

Yan Wu

Name: Yan Wu

TRADUCCIÓN AL ESPAÑOL DEL DOCUMENTO DE CESIÓN A
GENENTECH, INC firmado por los cedentes y el cesionario.

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)

1. País: Estados Unidos de América

Este documento público

2. ha sido firmado por T. Lawrence
3. actuando en capacidad de Funcionario que Certifica
4. lleva el sello/timbre de la Oficina de Marcas y Patentes de E.U.

Certificado

5. en Washington, D.C.
6. el veintiocho de noviembre de 2008
7. por el Funcionario de Autenticación Asistente, Departamento de Estado de los Estados Unidos.
8. No. 09006307-14
9. Sello/timbre

10. Firma

(Firma)

Patrick O. Hatchett

[Sello]

LOS ESTADOS UNIDOS DE AMÉRICA
A TODO AQUEL QUE PUEDA LLEGAR LA PRESENTE:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS
Oficina de Marcas y Patentes

14 de Noviembre 2008

LA PRESENTE CERTIFICA QUE EL ANEXO ES UNA COPIA VERDADERA
DE LOS ARCHIVOS DE ESTA OFICINA DE UN DOCUMENTO
ARCHIVADO EL 17 DE JULIO DE 2006.

Por la autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Marcas y Patentes de los Estados Unidos

(Firma)
T. LAWRENCE
Funcionario que certifica

Hay un sello que dice:
Oficina de Marcas y Patentes de Estados Unidos
Departamento de Comercio

517

CESIÓN DE PATENTE

Versión electrónica v1.1

Versión de la hoja v1.1

TIPO DE PRESENTACIÓN:	CESIÓN NUEVA
NATURALEZA DEL ACUERDO:	CESIÓN

DATOS DE LA PARTE CEDENTE

Nombre	Fecha de ejecución
Minhong Yang	07/05/2006
Yan Wu	07/05/2006

DATOS DE LA PARTE QUE RECIBE

Nombre:	Genentech, Inc.
Dirección:	1 DNA Way
Dirección Interna:	MS-49
Ciudad:	South San Francisco
Estado/Pais:	CALIFORNIA
Código Postal:	94080

NÚMERO DE PROPIETARIOS Total: 1

Tipo de Propiedad	Número
Número de solicitud:	60811349

DATOS DE CORRESPONDENCIA

Número de Fax: (650)952-9881

La correspondencia será enviada por Correo de Estados Unidos cuando los intentos de hacerlo por fax no sean exitosos.

Teléfono: 650 467 6222

Correo electrónico: pgolden@gene.com

Nombre del destinatario: Cara M. Coburn

Dirección Línea 1: 1 DNA Way

Dirección Línea 2: MS-49

Dirección Línea 4: South San Francisco, CALIFORNIA 94080

NÚMERO DE EXPEDIENTE DE ABOGADO:	PR2336
NOMBRE DEL REMITENTE:	Cara M. Coburn

Anexos totales:3

Fuente=assignment- 07-07-06 – LYS2LEJ#page1.tif

500123470

PATENTE

ROLLO: 017895 CUADRO: 0783

480

64

Fuente=assignment- 07-07-06 – LYS2LEJ#page2.tif

Fuente=assignment- 07-07-06 – LYS2LEJ#page3.tif

500123470

PATENTE

ROLLO: 017895 CUADRO: 0784

CESIÓN

CONSIDERANDO QUE, Minhong Yang, un ciudadano de los E.U.A., residente en **411 Nantucket Street, Foster City, CA 94404**, y Yan Wu, un ciudadano de los E.U.A., residente en **846 Andromeda Lane, Foster City, CA 94404**, (en adelante denominado como "CEDENTES"), han inventado una invención nueva y útil

ANTICUERPOS ANTI-DLL4 Y MÉTODOS QUE LOS USAN

para la cual se presentó una solicitud provisional con Serie No. 60/811,349 (Expediente No. PR2336) por ella el 6 de junio de 2006; y

CONSIDERANDO QUE, GENENTECH, INC., una corporación organizada y existente bajo y por virtud de las leyes del Estado de Delaware, que tiene oficinas en 1 DNA Way, South San Francisco, California 94080-4990, está deseosa de adquirir un interés en y para dicha invención, y en y para las patentes que se obtendrán de la misma;

AHORA, POR LO TANTO, téngase por sabido por todo aquel que le concierna:

Que por una consideración buena y valiosa el recibo de la cual se reconoce por la presente, dichos CEDENTES han y por la presente venden, ceden, transfieren y traspasan a dicha GENENTECH, INC. sus sucesores y cesionarios, el derecho, título e interés completo y exclusivo incluyendo todos los derechos bajo la Convención de Paris para la Protección de la Propiedad Industrial, en y para dicha invención, y en y para cualquiera y todas las patentes que se concedan y emitan para la misma o cualquier continuación, división, renovación, o sustitución de la misma, y en cuanto a patentes cualquier reemisión o reexaminación de las mismas, no solo para, por y en los Estados Unidos de América, sus territorios y posesiones, sin para, por y en todos los otros países; y se ha y por la presente se autoriza y solicita que las agencias gubernamentales respectivas emitan dichas patentes a GENENTECH, INC. de acuerdo con esta cesión.

Dicho CEDENTES garantizan y acuerdan cooperar con GENENTECH, INC., para posibilitar a dicha GENENTECH, INC., a disfrutar hasta su máxima extensión el derecho, título e interés aquí cedido en Estados Unidos y los países extranjeros. Tal cooperación por dichos CEDENTES incluye la pronta producción de hechos y documentos pertinentes, dando testimonio, ejecutando peticiones, juramentos, especificaciones, declaraciones u otros documentos, y otra ayuda todas hasta el punto considerado necesario o deseable por dichas GENENTECH, INC. (a) para perfeccionar el derecho, título e interés aquí cedido; (b) para procesar cualquiera de dichas solicitudes; (c) para presentar y procesar solicitudes de reemisión de cualquiera de dichas patentes; (d) para procesos de interferencia u otros procesos de prioridad que involucren dicha invención; y (e) para procedimientos legales que involucren dicha invención y cualquier solicitud de la misma y cualquier patente concedida sobre la misma, incluyendo sin limitación procedimientos de oposición, procedimientos de cancelación, disputas de prioridad, procesos de uso público, acciones de violación y acciones de la corte; con la condición que los gastos incurridos por dicho CEDENTES al proporcionar dicha cooperación deban ser pagados por GENENTECH, INC.

Los términos y garantías de esta cesión deben actuar en beneficio de dicha GENENTECH, INC. sus sucesores, cesionarios y otros representantes legales, y deberá ser obligante sobre dichos CEDENTES, sus respectivos herederos, representantes legales y cesionarios.

71

Dichos CEDENTES por la presente garantizan y manifiestan que no han entrado y no entrará en ninguna cesión, contrato o entendimiento en conflicto con la presente.

EN TESTIMONIO DE LO CUAL se suscriben como sigue:

South San Francisco
Julio 5, 2006

(firma)
Nombre: Minhong Yan

Fecha

South San Francisco

Fecha

(firma)
Nombre: Yan Wu

PATENTE
ROLLO: 017895 CUADRO: 0786

Dichos CEDENTES por la presente garantizan y manifiestan que no han entrado y no entrará en ninguna cesión, contrato o entendimiento en conflicto con la presente.

EN TESTIMONIO DE LO CUAL se suscriben como sigue:

South San Francisco

Fecha

Nombre: Minhong Yan

South San Francisco
Julio 5, 2006

Fecha

_____(Firma)
Nombre: Yan Wu

ARCHIVADO: 07/07/2006

PATENTE
ROLLO: 017895 CUADRO: 0787

HK

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document

2. has been signed by T. Lawrence

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U.S. Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the twenty-eighth of November, 2008

7. by Assistant Authentication Officer, United States Department of State

8. No. 09006307-13

9. Seal/Stamp:

10. Signature:



Patrick O. Hatchett

A 7156699

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

November 14, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
DECEMBER 18, 2006.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



T. LAWRENCE
Certifying Officer



PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Minhong Yan	12/04/2006
Yan Wu	12/04/2006
RECEIVING PARTY DATA	
Name:	Genentech, Inc.
Street Address:	1 DNA Way
Internal Address:	MS-49
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	60866772
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650 467 2607
Email:	pgolden@gene.com
Correspondent Name:	Grant Kalinowski
Address Line 1:	1 DNA Way
Address Line 2:	MS-49
Address Line 4:	South San Francisco, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	PR2336-1
NAME OF SUBMITTER:	Grant Kalinowski
Total Attachments: 4 source=PR2336#page1.tif	

CH \$40.00 60866772

500195631

**PATENT
REEL: 018648 FRAME: 0772**

27

source=PR2336#page2.tif
source=PR2336#page3.tif
source=PR2336#page4.tif

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

Commissioner for Patents: Please record the attached original documents or copy thereof.

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

Atty Dkt No: PR2336-1

1. Name of conveying party(ies):

Minhong Yan, Foster City, CA
Yan Wu, Foster City, CA

Additional name(s) of conveying party(ies) attached? _ Yes ☒ No

2. Name and address of receiving party(ies):

Name: GENENTECH, INC.

Internal Address:

Street Address: 1 DNA Way

City: South San Francisco State: California

ZIP: 94080-4990

Additional name(s) & address(es) attached? _ Yes ☒ No

3. Nature of conveyance:

☒ Assignment

Merger

Security Agreement

Change of Name

Other:

Execution Date: 04-DEC-2006

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 60/866,772

B. Patent No.(s)

Additional numbers attached? _ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Grant Kalinowski
GENENTECH, INC.
1 DNA Way
South San Francisco, CA 94080

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$ 40.00

_ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number:

07-0630


DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Grant Kalinowski

Name of Person Signing
Registration No. 48,314


Signature

Date

12/18/06

Total number of pages comprising cover sheet, attachments and document: 4

Revised (10/11/95)

#229784

**PATENT
REEL: 018648 FRAME: 0774**

ASSIGNMENT

WHEREAS, Minhong Yan, a citizen of the USA, residing at 411 Nantucket Street, Foster City, CA 94404, and Yan Wu, a citizen of the USA, residing at 846 Andromeda Lane, Foster City, CA 94404, (hereinafter "ASSIGNORS"), have invented a new and useful invention in

ANTI-DLL4 ANTIBODIES AND METHODS USING SAME

for which a provisional application Serial No. 60/866,772 (Docket No. PR2336-1) has been filed by them on 21-NOV-2006; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4490, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

CD

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco

Date

Name: Minhong Yan

South San Francisco

Date

12/4/2006

Name: Yan Wu

CP1

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco

12/14/2006
Date

Mirrhong Yan
Name: Mirrhong Yan

South San Francisco

Date

Name: Yan Wu

67

TRADUCCIÓN AL ESPAÑOL DEL DOCUMENTO DE CESIÓN A
GENENTECH, INC firmado por los cedentes y el cesionario.

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)

1. País: Estados Unidos de América

Este documento público

2. ha sido firmado por T. Lawrence
3. actuando en capacidad de Funcionario que Certifica
4. lleva el sello/timbre de la Oficina de Marcas y Patentes de E.U.

Certificado

5. en Washington, D.C.
6. el veintiocho de noviembre de 2008
7. por el Funcionario de Autenticación Asistente, Departamento de Estado de los Estados Unidos.
8. No. 09006307-13
9. Sello/timbre

10. Firma

(Firma)

Patrick O. Hatchett

[Sello]



LOS ESTADOS UNIDOS DE AMÉRICA
A TODO AQUEL QUE PUEDA LLEGAR LA PRESENTE:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS
Oficina de Marcas y Patentes

14 de Noviembre 2008

LA PRESENTE CERTIFICA QUE EL ANEXO ES UNA COPIA VERDADERA
DE LOS ARCHIVOS DE ESTA OFICINA DE UN DOCUMENTO
ARCHIVADO EL 18 DE DICIEMBRE DE 2006.

Por la autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Marcas y Patentes de los Estados Unidos

(Firma)
T. LAWRENCE
Funcionario que certifica

Hay un sello que dice:
Oficina de Marcas y Patentes de Estados Unidos
Departamento de Comercio

65

CESIÓN DE PATENTE

Versión electrónica v1.1

Versión de la hoja v1.1

TIPO DE PRESENTACIÓN:	CESIÓN NUEVA
NATURALEZA DEL ACUERDO:	CESIÓN

DATOS DE LA PARTE CEDENTE

Nombre	Fecha de ejecución
Minhong Yang	12/04/2006
Yan Wu	12/04/2006

DATOS DE LA PARTE QUE RECIBE

Nombre:	Genentech, Inc.
Dirección:	1 DNA Way
Dirección Interna:	MS-49
Ciudad:	South San Francisco
Estado/País:	CALIFORNIA
Código Postal:	94080

NÚMERO DE PROPIETARIOS Total: 1

Tipo de Propiedad	Número
Número de solicitud:	60866772

DATOS DE CORRESPONDENCIA

Número de Fax: (650)952-9881

La correspondencia será enviada por Correo de Estados Unidos cuando los intentos de hacerlo por fax no sean exitosos.

Teléfono: 650 467 2607

Correo electrónico: pgolden@gene.com

Nombre del destinatario: Grant Kalinowski

Dirección Línea 1: 1 DNA Way

Dirección Línea 2: MS-49

Dirección Línea 4: South San Francisco, CALIFORNIA 94080

NÚMERO DE EXPEDIENTE DE ABOGADO:	PR2336-1
NOMBRE DEL REMITENTE:	Grant Kalinowski

Anexos totales:4

Fuente=PR2336#page1.tif

500195631

PATENTE

ROLLO: 018648 CUADRO: 0772

PATENTE

ROLLO: 018648 CUADRO: 0773

69

Dichos CEDENTES por la presente garantizan y manifiestan que no han entrado y no entrará en ninguna cesión, contrato o entendimiento en conflicto con la presente.

EN TESTIMONIO DE LO CUAL se suscriben como sigue:

South San Francisco

Fecha

Nombre: Minhong Yan

South San Francisco
Diciembre 4, 2006

Fecha

(firma)
Nombre: Yan Wu



REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Folio 502

2020
Bogotá D.C.,

Doctor(a)
CADENA SARMIENTO JUAN PABLO
Apoderado(a) y/o Representante de
GENENTECH, INC.

REFERENCIA	Radicación No.	08 129885
	Solicitud internacional	PCT/US2007/070513
	Fecha inicio fase nacional	06/01/2009
	Trámite	11
	Evento	378
	Actuación	416
	Oficio No.	9035
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC,

16 OCT. 2009

ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

jfernand